

**NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Scoping**

**Guselkumab for previously treated moderately to severely active Crohn's disease [ID6238]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- |   |
|---|
| 1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|---|

Yes, the company noted during consultation that inflammatory bowel disease may be classed as a disability depending on the effect it has on a person's daily life.
--

It also noted that an additional treatment option which can be administered at home may reduce inequalities and increase adherence for people with inflammatory bowel disease.
--

- |   |
|---|
| 2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|---|

Where appropriate, the committee may consider whether its recommendation could result in less favourable treatment for reasons related to a person's disability.
--

Where appropriate, the committee may consider whether there are additional benefits that have not been captured in the economic modelling.
--

- |  |
|--|
| 3. Has any change to the draft scope been agreed to highlight potential equality issues? |
|--|

No
----

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?
No

**Approved by Associate Director (name):** .....Janet Robertson.....

**Date:** 26 July 2024